Early childhood infection with human herpes virus type 6 (hhv-6) as a protection against the development of ige sensitization, atopic disease and allergy in young children
OwnerInger Nordstrom, Kristina Erikssoninventors
Life of this patent
Estimating the term…
Abstract
The present invention discloses a use of human herpes virus 6 (HHV-6) or derivatives thereof, for the manufacture of a pharmaceutical composition intended to be administered during early childhood, for the prevention of IgE sensitization and allergy development in young children. Examples of viral compositions include, but are not limited to live human herpes virus 6 (HHV-6).
Claims21
A use of human herpes virus 6 (HHV-6) or derivatives there of in the manufacture of a pharmaceutical composition for the prevention of IgE sensitization, atopy or atopic disease including asthma in children.
A method for preventing IgE-sensitization, allergy, autoimmune disorders and/or inflammatory diseases in humans, by administering a therapeutic effective amount of a human herpes virus 6 (HHV-6) to children no later than 18 months after birth.
Dependencies are inferred from the claim text.